Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Already had mine. 2 cups of coffee does the trick.
Aryc, mop--had many Jags. If you're going to buy one or restore one, I suggest a XJC. Rare 2 door with the 4.2 liter straight 6. But any are good after 1983 and before Ford was involved in late 1987. Fast Ed.
Should be PR. Stupid auto correct.
Will someone please post the text or link to the problem? Ths
When exactly does the reverse split take place?
Au contraire
My guess based on what I did for a living is about 100k -200k. Possibly a piece of the action if approved . Just for the consulting work only. Imo.
Do a little DD. $250k escrowed for audit.
Owcp was over $3/share at one point. Wouldn't that be fun for Bldv!
Don't blame you. This is almost the exact path of Hugo and we got whacked bad even in Charlotte. No power for 14 days.
Where exactly are you at in NC?
Good luck to you. I live in Charlotte. This one reminds me of Hugo.
Reminds me of the movie "major league " Randy Quaid in the bleachers.
If I might ask, what is the other?
Im thinking this might actually be a real business, so our losses might be recouped with a really nice gain. We'll see.
But did you not get your free goat from jqm? Sorry, been here for a long time, might as well ride it out.
And imagine this: Insurance companies will provide incentives and pay for their insured people to have DNA sequencing done so that their actuaries can access internal financial risk. Much like the Wellness Programs that most offer now.
$ARYC$. people need to understand how big this news is. This from publication "Modern Healthcare" yesterday. Just one of thousands to come.
Geisinger CEO: Routine DNA sequencing will save money
By Rachel Z. Arndt | May 7, 2018
Geisinger patients won't have to foot any upfront costs as the health system rolls out DNA sequencing as part of routine care, and the program will ultimately reap cost savings by catching diseases earlier, the system's CEO said Monday.
Donors and Geisinger's insurance company will take on the financial burden, and the health system will spend "under $5 million" to sequence a "huge number" of patients' DNA in a new program, Geisinger President and CEO Dr. David Feinberg said. That money will go to the cost of the actual tests, which he estimates will range from $300 to $500 per patient.
Under the new program, all Geisinger patients will have the chance to have their DNA sequenced.
Feinberg intends DNA sequencing to eventually be as routine as checking for high cholesterol. But for now, the health system is starting with a pilot program to sequence 1,000 patients' DNA.
To outside experts, it's a sign of things to come.
"We are reaching the point where genomic sequencing is cost-effective and inevitably going mainstream," said Nilesh Chandra, a healthcare consultant with PA Consulting Group. "We expect more systems to adopt similar strategies in the future."
Geisinger will cover the cost of every patient's sequencing, no matter the patient's insurer, and the health system is prepared for a long-term investment.
"It's probably going to take decades to really prove that this really works," Feinberg said. "Our gut feeling is that we will be able to show that it's sustainable and actually a decrease in cost overall."
That will lead to greater commercial payer coverage of genetic testing, Feinberg predicted. As commercial insurers see the money Geisinger saves on the patients covered by its own plan, they will follow suit.
Though Geisinger will cover the cost of the test itself, patients will still be responsible—whether through copays or otherwise—for the costs associated with follow-up care, such as genetic counseling.
That follow-up is important, according to Morris Panner, CEO of Ambra Health, a medical imaging software company. But it's still unclear what providers actually do with patients' genetic information.
Geisinger providers will use the testing data to improve the quality of care for patients, and Geisinger researchers will use the de-identified information, Geisinger Chief Scientific Officer David Ledbetter said.
Geisinger researchers already study the DNA of patients enrolled in the health system's MyCode precision medicine program, which was established in 2014 in partnership with the Regeneron Genetics Center.
Geisinger is not alone in pursuing precision medicine. Most recently, the National Institutes of Health launched its All of Us initiative, a program to collect the health records and DNA of 1 million people to advance precision medicine. The NIH will make those data freely available to researchers starting in 2019.
Meanwhile, the consumer genetic testing market is bursting at the seams. As of Aug. 1, 2017, there were about 75,000 genetic tests available, according to a new study published in Health Affairs. But coverage for these tests is inconsistent, they wrote. "There are concerns that patients may face high out-of-pocket spending for many genetic tests," they wrote.
The clinical usefulness of these tests remains somewhat unknown, according to the study.
"The good thing about Geisinger is that within their system, they should be able to access the data and see what kind of impact it's having," said Patricia Deverka, one of the authors and a researcher at the American Institutes for Research.
Ok, now I'm confused. Is Wong the attorney for Aryc or Taub? Not up on legalese, so not sure what this means. Tia for responding.
They drank all the biodiesel from Belize and died. Lol.
Curious myself.
Should be 45 days from quarters end, unless an extension. August 15.
Lol. Maybe he's spending time with the Tijuana Brass. At least get his name right.
Delsurfer and Mike,
Here is my take on the tweet (after 35 years in accounting and financial consulting). The auditors have finished, at least with that part of it, and returned a somewhat random list to the company for testing (confirmation). Usually 10-15 total. The company has a form letter to send to the AP list on the company's letterhead with a return postal return to the auditing firm asking for verification of the amounts owed as of X date. They ask for the return within 10-14 days. They really do not expect all of them to be returned, but just a few of the sample gives them confidence in what they have audited. Same goes for AR, bank statements and loans (which each are verified, not random tested)and the like.
It does show to me that progress is being made, and financials are not too far off.
My take only, but hope this helps.
--Fast Ed
Thanks MikeCr.
Tks, Delsurfer. Makes sense. That article said that Pinner was a division of ARYC, and their website just mentions it as "Our Laboratory", which in my mind says--we use them for our tests. I do believe that the lab revenue would be at least 50% or more of the retail cost, whatever it is, of the test. May be a fixed price Thoughts?
If Pinner is a division of Arrayit, the numbers should show up in the consolidated financial statements. Their website and this article claims to have "over a half million satisfied clients". Based on the math, 500,000 clients x $490 per test= $245 million dollars in revenue. Let's say that even if they are not a 100% owned division (or company), and Ayrc is just the servicing lab. AYRC should receive at least 50% service revenue (which will show up in the financials (over X number of years), it's still a boat load of revenue.
Even at lower % its still a ton
50% = $122.5 M
25% = $61.25 M
Going to be interesting to see.
Link please.
JJ,. Think you have some dup's in there. One that jumped out at me was a 53,700. Looking on my phone, so tough to tell how many. Still is looking great tho.
Patience, Grasshopper
me thinks ,30 is way too low. put it at $1 minimum, and watch the movement. GLTY and all
A few other random thoughts on ARYC, and then i'll go back to lurking in the weeds. All IMHO.
1. I truly believe they have great technology, which is just beginning to take off (Protein Microarrays vs. DNA). Tip of the Iceberg. That said, some of the smartest people I've ever met are not necessarily wise when it comes to Business or Finance.
2. Financials-- When they do come out, I don't expect any great bottom line. I do expect them to give us the transparency needed looking forward. I do not expect them until much later (end of March or later), but if they are issued earlier, I'll be happy with that. Been through many audits on behalf and alongside my clients, and delays are the norm, especially with a publicly traded entity. I've had auditors give me a timeline of 45 days, only to have them delayed to 90 or 120.
3. MM manipulation-- yes it does occur, it's all done by computers and algorithms designed to make the most money for the MM. Human intervention rarely occurs.
My two cents,
Fast Ed
Connecting some dots here:
From Twitter
Arrayit manufacturing team completes 20,000 blood card production run with $6.9M 2017 life science revenue potential (link: http://arrayit.com/Products/Protein_Microarrays/Blood_Card/blood_card.html) arrayit.com/Products/Prote…
Methinks this production run has a lot to do with the Pinnertest.
$6.9M divided by 20,000 cards= $345 per test.
Might be, or might be other tests, but seem plausible.
Thank you. Lost a ton of money for something I believed in. Swift is less than honorable, let's hope the science goes forward.
Tks, Jf. I've always kept an amount that would be a round number of a 1:35 spinout of Shining Tree (remember that possibility?) So, to your knowledge, we still hold 100% of Shining Tree? I vaguely remember that part of that may have been sold?
Jfburke, question (this is my bad because I haven't been following for a couple of years), but what if anything survives with SRSR. Do they still have Shining Tree or DeadMoose? Will SRSR continue to trade as a separate entity? I know the Nio was spun out as a wholly owned subsidiary, which I'm assuming is what is being merged.
Tks
Fast Ed
certainly hope you're correct. It was vague in the PR.
So, if I read this correctly, my 1 mil remaining shares becomes 52,500 shares in the new company, then they are going to enact a 1:12,500 reverse split, which will leave me with a whopping total of 4.2 shares in the new entity. Am I reading this correctly?
Amen brother!!!!!
I understand that. Neither do I.